Elio Scarpini

List of Publications by Year
in descending order

345 papers	21,097 citations	14655 66 h-index	14759 127 g-index
347 all docs	347 docs citations	347 times ranked	26109 citing authors

#	Article	IF	Citations
1	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
2	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics, 2011, 43, 429-435.	21.4	1,708
3	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
4	Treatment of Alzheimer's disease; current status and new perspectives. Lancet Neurology, The, 2003, 2, 539-547.	10.2	664
5	Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurology, The, 2015, 14, 253-262.	10.2	432
6	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's and Dementia, 2011, 7, 386.	0.8	354
7	Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurology, The, 2007, 6, 501-512.	10.2	314
8	A Polymorphism in CALHM1 Influences Ca2+ Homeostasis, AÎ² Levels, and Alzheimer's Disease Risk. Cell, 2008, 133, 1149-1161.	28.9	310
9	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	10.2	302
10	Heterogeneity of Brain Glucose Metabolism in Mild Cognitive Impairment and Clinical Progression to Alzheimer Disease. Archives of Neurology, 2005, 62, 1728.	4.5	269
11	Intrathecal Chemokine Synthesis in Mild Cognitive Impairment and Alzheimer Disease. Archives of Neurology, 2006, 63, 538.	4.5	268
12	Efficacy of Souvenaid in Mild Alzheimer's Disease: Results from a Randomized, Controlled Trial. Journal of Alzheimer's Disease, 2012, 31, 225-236.	2.6	256
13	SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology, 2012, 79, 1556-1562.	1.1	252
14	Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain, 2008, 131, 3081-3091.	7.6	248
15	Molecular Mechanisms Involved in Lymphocyte Recruitment in Inflamed Brain Microvessels: Critical Roles for P-Selectin Glycoprotein Ligand-1 and Heterotrimeric Gi-Linked Receptors. Journal of Immunology, 2002, 168, 1940-1949.	0.8	246
16	Prolonged visual memory enhancement after direct current stimulation in Alzheimer's disease. Brain Stimulation, 2012, 5, 223-230.	1.6	245
17	Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2016, 3, 623-636.	3.7	207
18	Circulating miRNAs as Potential Biomarkers in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 1261-1267.	2.6	188

#	Article	IF	Citations
19	RhoA and Î¶ PKC Control Distinct Modalities of LFA-1 Activation by Chemokines. Immunity, 2004, 20, 25-35.	14.3	185
20	Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. Neurobiology of Aging, 2006, 27, 1763-1768.	3.1	185
21	Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 2006, 27, 262-269.	3.1	178
22	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	10.2	175
23	Selective DNA Methylation of BDNF Promoter in Bipolar Disorder: Differences Among Patients with BDI and BDII. Neuropsychopharmacology, 2012, 37, 1647-1655.	5.4	166
24	CD8+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1. Blood, 2003, 101, 4775-4782.	1.4	165
25	Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain, 2020, 143, 1632-1650.	7.6	158
26	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	2.5	155
27	Detection of Misfolded AÎ² Oligomers for Sensitive Biochemical Diagnosis of Alzheimerâ€™s Disease. Cell Reports, 2014, 7, 261-268.	6.4	154
28	Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. Neurobiology of Aging, 2018, 62, 191-196.	3.1	151
29	Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with Î²-amyloid [25â€“35]. Journal of Neuroimmunology, 1999, 93, 45-52.	2.3	148
30	Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis. Neuroscience Letters, 2011, 504, 9-12.	2.1	147
31	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain, 2015, 138, 918-931.	7.6	147
32	Heterozygous TREM2 mutations in frontotemporal dementia. Neurobiology of Aging, 2014, 35, 934.e7-934.e10.	3.1	134
33	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurology, The, 2019, 18, 1103-1111.	10.2	128
34	Transcranial direct current stimulation (tDCS) for fatigue in multiple sclerosis. NeuroRehabilitation, 2014, 34, 121-127.	1.3	126
35	Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Molecular Neurodegeneration, 2015, 10, 64.	10.8	121
36	Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients. Annals of Neurology, 2003, 53, 547-548.	5.3	115

#	Article	IF	Citations
37	Vascular endothelial growth factor gene variability is associated with increased risk for AD. Annals of Neurology, 2005, 57, 373-380.	5.3	115
38	Disease-modifying treatments for Alzheimerâ€™s disease. Therapeutic Advances in Neurological Disorders, 2011, 4, 203-216.	3.5	110
39	FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort. NeuroImage: Clinical, 2018, 18, 167-177.	2.7	108
40	Autosomal Dominant Frontotemporal Lobar Degeneration Due to the C9ORF72 Hexanucleotide Repeat Expansion: Late-Onset Psychotic Clinical Presentation. Biological Psychiatry, 2013, 74, 384-391.	1.3	105
41	Production of monocyte chemoattractant proteinâ€1 in amyotrophic lateral sclerosis. Muscle and Nerve, 2005, 32, 541-544.	2.2	104
42	Osteopontin is Increased in the Cerebrospinal Fluid of Patients with Alzheimer's Disease and Its Levels Correlate with Cognitive Decline. Journal of Alzheimer's Disease, 2010, 19, 1143-1148.	2.6	100
43	Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1938-1942.	3.0	98
44	Plasma levels of beta-amyloid (1â€“42) in Alzheimer's disease and mild cognitive impairment. Neurobiology of Aging, 2006, 27, 904-905.	3.1	97
45	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	10.2	97
46	MicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkers. Neuroscience Letters, 2012, 508, 4-8.	2.1	95
47	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 862-871.	0.8	93
48	IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease. Journal of the Neurological Sciences, 2002, 195, 41-46.	0.6	92
49	Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Multiple Sclerosis Journal, 2011, 17, 819-829.	3.0	88
50	Optimal Plasma Progranulin Cutoff Value for Predicting Null Progranulin Mutations in Neurodegenerative Diseases: A Multicenter Italian Study. Neurodegenerative Diseases, 2012, 9, 121-127.	1.4	88
51	Old and new acetylcholinesterase inhibitors for Alzheimerâ€™s disease. Expert Opinion on Investigational Drugs, 2016, 25, 1181-1187.	4.1	86
52	Î±-MSH Peptides Inhibit Production of Nitric Oxide and Tumor Necrosis Factor-Î± by Microglial Cells Activated with Î²-Amyloid and Interferon Î³. Biochemical and Biophysical Research Communications, 1999, 263, 251-256.	2.1	85
53	Epigenetic modulation of BDNF gene: Differences in DNA methylation between unipolar and bipolar patients. Journal of Affective Disorders, 2014, 166, 330-333.	4.1	85
54	Pioglitazone for the treatment of Alzheimerâ€™s disease. Expert Opinion on Investigational Drugs, 2017, 26, 97-101.	4.1	85

#	Article	IF	Citations
55	Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8050-8054.	7.1	84
56	Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnestic Mild Cognitive Impairment converted to Alzheimer's disease. Journal of the Neurological Sciences, 2009, 287, 291-293.	0.6	83
57	Clinical phenotypes and genetic biomarkers of FTLD. Journal of Neural Transmission, 2012, 119, 851-860.	2.8	83
58	Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations. Neurobiology of Aging, 2011, 32, 756.e11-756.e15.	3.1	82
59	Progress in Alzheimerâ€™s disease. Journal of Neurology, 2012, 259, 201-211.	3.6	79
60	Epigenetic Modulation of BDNF Gene in Patients with Major Depressive Disorder. Biological Psychiatry, 2013, 73, e6-e7.	1.3	79
61	MCP-1 in Alzheimerâ€™s disease patients: A-2518G polymorphism and serum levels. Neurobiology of Aging, 2004, 25, 1169-1173.	3.1	77
62	Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration. Journal of Neurology, 2008, 255, 539-544.	3.6	76
63	Loss of function mutations in the progranulin gene are related to pro-inflammatory cytokine dysregulation in frontotemporal lobar degeneration patients. Journal of Neuroinflammation, 2011, 8, 65.	7.2	76
64	Weight Loss Predicts Progression of Mild Cognitive Impairment to Alzheimerâ€™s Disease. PLoS ONE, 2016, 11, e0151710.	2.5	76
65	Innate Immune System and Inflammation in Alzheimer's Disease: From Pathogenesis to Treatment. NeuroImmunoModulation, 2014, 21, 79-87.	1.8	74
66	Psychiatric Symptoms in Frontotemporal Dementia: Epidemiology, Phenotypes, and Differential Diagnosis. Biological Psychiatry, 2015, 78, 684-692.	1.3	73
67	CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo- Controlled Study. Current Alzheimer Research, 2013, 10, 742-753.	1.4	73
68	Expression and Genetic Analysis of MicroRNAs Involved in Multiple Sclerosis. International Journal of Molecular Sciences, 2013, 14, 4375-4384.	4.1	71
69	Physical Activity Reduces the Risk of Dementia in Mild Cognitive Impairment Subjects: A Cohort Study. Journal of Alzheimer's Disease, 2014, 39, 833-839.	2.6	71
70	Transcranial Direct Current Stimulation Modulates Cortical Neuronal Activity in Alzheimer's Disease. Frontiers in Neuroscience, 2016, 10, 134.	2.8	66
71	From Genotype to Phenotype: Two Cases of Genetic Frontotemporal Lobar Degeneration with Premorbid Bipolar Disorder. Journal of Alzheimer's Disease, 2011, 27, 791-797.	2.6	65
72	Csf p-tau₁₈₁/tau ratio as biomarker for TDP pathology in frontotemporal dementia. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 86-91.	1.7	65

#	Article	IF	Citations
73	Epigenetic Regulation of Fatty Acid Amide Hydrolase in Alzheimer Disease. PLoS ONE, 2012, 7, e39186.	2.5	64
74	Progranulin genetic variations in frontotemporal lobar degeneration: evidence for low mutation frequency in an Italian clinical series. Neurogenetics, 2008, 9, 197-205.	1.4	63
75	White matter hyperintensities are seen only in GRN mutation carriers in the GENFI cohort. NeuroImage: Clinical, 2017, 15, 171-180.	2.7	63
76	Macrophage infiltration and death in the nerve during the early phases of experimental diabetic neuropathy: a process concomitant with endoneurial induction of IL-1Î² and p75NTR. Journal of the Neurological Sciences, 2002, 195, 35-40.	0.6	62
77	Phenotypic Heterogeneity of the GRN Asp22fs Mutation in a Large Italian Kindred. Journal of Alzheimer's Disease, 2011, 24, 253-259.	2.6	62
78	An Emerging Role for Long Non-Coding RNA Dysregulation in Neurological Disorders. International Journal of Molecular Sciences, 2013, 14, 20427-20442.	4.1	62
79	MicroRNAs as Active Players in the Pathogenesis of Multiple Sclerosis. International Journal of Molecular Sciences, 2012, 13, 13227-13239.	4.1	61
80	Expression of the Transcription Factor Sp1 and its Regulatory hsa-miR-29b in Peripheral Blood Mononuclear Cells from Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 35, 487-494.	2.6	61
81	Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathyâ€“Related Inflammation. Neurology, 2021, 97, e1809-e1822.	1.1	61
82	Early Onset Behavioral Variant Frontotemporal Dementia due to the C9ORF72 Hexanucleotide Repeat Expansion: Psychiatric Clinical Presentations. Journal of Alzheimer's Disease, 2012, 31, 447-452.	2.6	60
83	MiRNA Profiling in Plasma Neural-Derived Small Extracellular Vesicles from Patients with Alzheimerâ€™s Disease. Cells, 2020, 9, 1443.	4.1	60
84	Rs5848 Variant Influences GRN mRNA Levels in Brain and Peripheral Mononuclear Cells in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 18, 603-612.	2.6	59
85	Recognition of viral and self-antigens by T H 1 and T H 1/T H 17 central memory cells in patients with multiple sclerosis reveals distinct roles in immune surveillance and relapses. Journal of Allergy and Clinical Immunology, 2017, 140, 797-808.	2.9	59
86	An APOE Haplotype Associated with Decreased Îµ4 Expression Increases the Risk of Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 24, 235-245.	2.6	58
87	Inflammation and oxidative damage in Alzheimer s disease friend or foe. Frontiers in Bioscience - Scholar, 2011, S3, 252-266.	2.1	57
88	Role of hnRNP-A1 and miR-590-3p in Neuronal Death: Genetics and Expression Analysis in Patients with Alzheimer Disease and Frontotemporal Lobar Degeneration. Rejuvenation Research, 2011, 14, 275-281.	1.8	57
89	Role of Oxidative Damage in Alzheimerâ€™s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery. Antioxidants, 2021, 10, 1353.	5.1	57
90	Expression of nerve growth factor receptor during human peripheral nerve development. Developmental Biology, 1988, 125, 301-310.	2.0	56

#	Article	IF	Citations
91	Immunoproteasome LMP2 60HH Variant Alters MBP Epitope Generation and Reduces the Risk to Develop Multiple Sclerosis in Italian Female Population. PLoS ONE, 2010, 5, e9287.	2.5	56
92	The Enigmatic Role of Viruses in Multiple Sclerosis: Molecular Mimicry or Disturbed Immune Surveillance?. Trends in Immunology, 2017, 38, 498-512.	6.8	56
93	Disease-modifying drugs in Alzheimer's disease. Drug Design, Development and Therapy, 2013, 7, 1471.	4.3	55
94	Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study. Brain, 2017, 140, 1784-1791.	7.6	55
95	Is M129V of PRNP gene associated with Alzheimer's disease? A case-control study and a meta-analysis. Neurobiology of Aging, 2006, 27, 770.e1-770.e5.	3.1	54
96	The CALHM1 P86L Polymorphism is a Genetic Modifier of Age at Onset in Alzheimer's Disease: a Meta-Analysis Study. Journal of Alzheimer's Disease, 2010, 22, 247-255.	2.6	54
97	Role of Genetics and Epigenetics in the Pathogenesis of Alzheimerâ€™s Disease and Frontotemporal Dementia. Journal of Alzheimer's Disease, 2018, 62, 913-932.	2.6	54
98	Decrease of nerve Na+,K+-ATPase activity in the pathogenesis of human diabetic neuropathy. Journal of the Neurological Sciences, 1993, 120, 159-167.	0.6	52
99	Efficient Recruitment of Lymphocytes in Inflamed Brain Venules Requires Expression of Cutaneous Lymphocyte Antigen and Fucosyltransferase-VII. Journal of Immunology, 2005, 174, 5805-5813.	0.8	50
100	The C9ORF72 hexanucleotide repeat expansion is a rare cause of schizophrenia. Neurobiology of Aging, 2014, 35, 1214.e7-1214.e10.	3.1	49
101	The human astrocytoma cell line U373MG produces monocyte chemotactic protein (MCP)-1 upon stimulation with Î²-amyloid protein. Neuroscience Letters, 2000, 283, 177-180.	2.1	48
102	A genome-wide screening and SNPs-to-genes approach to identify novel genetic risk factors associated with frontotemporal dementia. Neurobiology of Aging, 2015, 36, 2904.e13-2904.e26.	3.1	48
103	Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers. Annals of Clinical and Translational Neurology, 2018, 5, 583-597.	3.7	48
104	Regulatory T Cells Suppress the Late Phase of the Immune Response in Lymph Nodes through P-Selectin Glycoprotein Ligand-1. Journal of Immunology, 2013, 191, 5489-5500.	0.8	47
105	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. Neurobiology of Aging, 2019, 77, 169-177.	3.1	47
106	A Functional Variant in ERAP1 Predisposes to Multiple Sclerosis. PLoS ONE, 2012, 7, e29931.	2.5	46
107	Cerebrospinal Fluid Biomarkers in Progranulin Mutations Carriers. Journal of Alzheimer's Disease, 2011, 27, 781-790.	2.6	45
108	Tolerability and Safety of Souvenaid in Patients with Mild Alzheimer's Disease: Results of Multi-Center, 24-Week, Open-Label Extension Study. Journal of Alzheimer's Disease, 2015, 44, 471-480.	2.6	44

#	Article	IF	Citations
109	Pharmacogenomics in Alzheimer's disease: a genome-wide association study of response to cholinesterase inhibitors. Neurobiology of Aging, 2013, 34, 1711.e7-1711.e13.	3.1	43
110	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. JAMA Network Open, 2021, 4, e2030194.	5.9	42
111	Treatment of Alzheimers Disease: Symptomatic and Disease-Modifying Approaches. Current Aging Science, 2010, 3, 46-56.	1.2	41
112	Growth Arrest Specific 6 Concentration is Increased in the Cerebrospinal Fluid of Patients with Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 59-65.	2.6	41
113	QUANTITATIVE ASSESSMENT OF CLASS II MOLECULES IN NORMAL AND PATHOLOGICAL NERVES. Brain, 1990, 113, 659-675.	7.6	40
114	Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-Î². Journal of the Neurological Sciences, 2006, 244, 97-102.	0.6	40
115	Does Vascular Burden Contribute to the Progression of Mild Cognitive Impairment to Dementia?. Dementia and Geriatric Cognitive Disorders, 2012, 34, 235-243.	1.5	40
116	The SIRT2 polymorphism rs10410544 and risk of Alzheimer's disease in two Caucasian caseâ€“control cohorts. Alzheimer's and Dementia, 2013, 9, 392-399.	0.8	40
117	Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. Neurobiology of Aging, 2018, 62, 245.e9-245.e12.	3.1	40
118	Establishment of Schwann cell cultures from adult rat peripheral nerves. Experimental Neurology, 1988, 102, 167-176.	4.1	39
119	Founder effect and estimation of the age of the Progranulin Thr272fs mutation in 14 Italian pedigrees with frontotemporal lobar degeneration. Neurobiology of Aging, 2011, 32, 555.e1-555.e8.	3.1	39
120	Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis. Journal of Neuroimmunology, 2016, 299, 81-83.	2.3	39
121	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	7.6	39
122	Presymptomatic white matter integrity loss in familial frontotemporal dementia in the <scp>GENFI</scp> cohort: A crossâ€sectional diffusion tensor imaging study. Annals of Clinical and Translational Neurology, 2018, 5, 1025-1036.	3.7	39
123	The loss of macular ganglion cells begins from the early stages of disease and correlates with brain atrophy in multiple sclerosis patients. Multiple Sclerosis Journal, 2019, 25, 31-38.	3.0	39
124	Immunological patterns identifying disease course and evolution in multiple sclerosis patients. Journal of Neuroimmunology, 2005, 165, 192-200.	2.3	38
125	Immunotherapy against amyloid pathology in Alzheimer's disease. Journal of the Neurological Sciences, 2013, 333, 50-54.	0.6	38
126	LncRNAs expression profile in peripheral blood mononuclear cells from multiple sclerosis patients. Journal of Neuroimmunology, 2018, 324, 129-135.	2.3	37

#	Article	IF	Citations
127	S-100 protein and laminin: Immunocytochemical markers for human Schwann cells in vitro. Experimental Neurology, 1986, 93, 77-83.	4.1	36
128	Influence of the Glu298Asp polymorphism of NOS3 on age at onset and homocysteine levels in AD patients. Neurobiology of Aging, 2005, 26, 789-794.	3.1	36
129	Frontotemporal lobar degeneration: current knowledge and future challenges. Journal of Neurology, 2012, 259, 2278-2286.	3.6	36
130	Safety of MF59-Adjuvanted Influenza Vaccination in the Elderly: Results of a Comparative Study of MF59-Adjuvanted Vaccine Versus Nonadjuvanted Influenza Vaccine in Northern Italy. American Journal of Epidemiology, 2013, 178, 1139-1145.	3.4	36
131	CSF Î²-amyloid and white matter damage: a new perspective on Alzheimerâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 352-357.	1.9	36
132	IL-33 and its decoy sST2 in patients with Alzheimerâ€™s disease and mild cognitive impairment. Journal of Neuroinflammation, 2020, 17, 174.	7.2	36
133	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, 500-514.	0.8	36
134	CCR2-64I polymorphism and CCR5Î”32 deletion in patients with Alzheimer's disease. Journal of the Neurological Sciences, 2004, 225, 79-83.	0.6	35
135	Inflammation in Neurodegenerative Disorders: Friend or Foe?. Current Aging Science, 2008, 1, 30-41.	1.2	35
136	Replication Study to Confirm the Role of CYP2D6 Polymorphism rs1080985 on Donepezil Efficacy in Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2012, 30, 745-749.	2.6	35
137	Screening of the PFN1 gene in sporadic amyotrophic lateral sclerosis and in frontotemporal dementia. Neurobiology of Aging, 2013, 34, 1517.e9-1517.e10.	3.1	35
138	Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease. Neurobiology of Aging, 2020, 87, 139.e1-139.e7.	3.1	35
139	VEGF genetic variability is associated with increased risk of developing Alzheimer's disease. Journal of the Neurological Sciences, 2009, 283, 66-68.	0.6	34
140	Progranulin Gene Variability and Plasma Levels in Bipolar Disorder and Schizophrenia. PLoS ONE, 2012, 7, e32164.	2.5	34
141	Distinct patterns of brain atrophy in Genetic Frontotemporal Dementia Initiative (GENFI) cohort revealed by visual rating scales. Alzheimer's Research and Therapy, 2018, 10, 46.	6.2	34
142	Interleukin-1beta and interferon-gamma induce proliferation and apoptosis in cultured Schwann cells. Journal of Neuroimmunology, 2002, 124, 29-35.	2.3	33
143	Heterosexual Pedophilia in a Frontotemporal Dementia Patient with a Mutation in the Progranulin Gene. Biological Psychiatry, 2011, 70, e43-e44.	1.3	33
144	Alzheimers Disease: From Pathogenesis to Disease-Modifying Approaches. CNS and Neurological Disorders - Drug Targets, 2011, 10, 163-174.	1.4	33

#	Article	IF	Citations
145	Defining the association of TMEM106B variants among frontotemporal lobar degeneration patients with GRN mutations andÂ C9orf72 repeat expansions. Neurobiology of Aging, 2014, 35, 2658.e1-2658.e5.	3.1	33
146	Body Mass Index Predicts Progression of Mild Cognitive Impairment to Dementia. Dementia and Geriatric Cognitive Disorders, 2016, 41, 172-180.	1.5	33
147	CSF Î²-amyloid as a putative biomarker of disease progression in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1085-1091.	3.0	33
148	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. NeuroImage, 2019, 189, 645-654.	4.2	33
149	Cessation versus Continuation of Galantamine Treatment after 12 Months of Therapy in Patients with Alzheimer's Disease: A Randomized, Double Blind, Placebo Controlled Withdrawal Trial. Journal of Alzheimer's Disease, 2011, 26, 211-220.	2.6	32
150	Genetics of Frontotemporal Lobar Degeneration. Frontiers in Neurology, 2012, 3, 52.	2.4	32
151	C9ORF72 hexanucleotide repeat expansion as a rare cause of bipolar disorder. Bipolar Disorders, 2014, 16, 448-449.	1.9	32
152	Association of a NOS1 promoter repeat with Alzheimer's disease. Neurobiology of Aging, 2008, 29, 1359-1365.	3.1	31
153	Role of OLR1 and Its Regulating hsa-miR369-3p in Alzheimer's Disease: Genetics and Expression Analysis. Journal of Alzheimer's Disease, 2011, 26, 787-793.	2.6	31
154	The Impact of Osteopontin Gene Variations on Multiple Sclerosis Development and Progression. Clinical and Developmental Immunology, 2012, 2012, 1-6.	3.3	31
155	Possible Association between SNAP-25 Single Nucleotide Polymorphisms and Alterations of Categorical Fluency and Functional MRI Parameters in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 1015-1028.	2.6	31
156	Expression of the low-affinity NGF receptor during human muscle development, regeneration, and in tissue culture. Muscle and Nerve, 1994, 17, 276-284.	2.2	30
157	Inducible nitric oxide synthase (iNOS) in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system. Experimental Neurology, 2004, 187, 350-358.	4.1	30
158	Gender-specific influence of the chromosome 16 chemokine gene cluster on the susceptibility to Multiple Sclerosis. Journal of the Neurological Sciences, 2008, 267, 86-90.	0.6	30
159	Progranulin gene (GRN) promoter methylation is increased in patients with sporadic frontotemporal lobar degeneration. Neurological Sciences, 2013, 34, 899-903.	1.9	30
160	Frontotemporal Dementia: Correlations Between Psychiatric Symptoms and Pathology. Annals of Neurology, 2020, 87, 950-961.	5.3	30
161	Exploring the role of BDNF DNA methylation and hydroxymethylation in patients with obsessive compulsive disorder. Journal of Psychiatric Research, 2019, 114, 17-23.	3.1	29
162	Interleukin-6 plasma level increases with age in an Italian elderly population (â€œThe Treviso) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 67 T 155-162.	3.0	28

#	Article	IF	Citations
163	GRN Variability Contributes to Sporadic Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2010, 19, 171-177.	2.6	28
164	A Novel MAPT Mutation Associated with the Clinical Phenotype of Progressive Nonfluent Aphasia. Journal of Alzheimer's Disease, 2011, 26, 19-26.	2.6	28
165	Reversible Mild Cognitive Impairment: The Role of Comorbidities at Baseline Evaluation. Journal of Alzheimer's Disease, 2016, 51, 57-67.	2.6	28
166	Amyloid PET as a marker of normal-appearing white matter early damage in multiple sclerosis: correlation with CSF Î²-amyloid levels and brain volumes. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 280-287.	6.4	28
167	Differential early subcortical involvement in genetic FTD within the GENFI cohort. NeuroImage: Clinical, 2021, 30, 102646.	2.7	28
168	Schwann cell undergoes apoptosis during experimental allergic neuritis (EAN). Journal of the Neurological Sciences, 1998, 161, 29-35.	0.6	27
169	Incomplete Penetrance of the C9ORF72 Hexanucleotide Repeat Expansions: Frequency in a Cohort of Geriatric Non-Demented Subjects. Journal of Alzheimer's Disease, 2014, 39, 19-22.	2.6	27
170	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. NeuroImage: Clinical, 2019, 24, 102077.	2.7	27
171	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain, 2022, 145, 1805-1817.	7.6	27
172	The T-786C NOS3 polymorphism in Alzheimer's disease: Association and influence on gene expression. Neuroscience Letters, 2005, 382, 300-303.	2.1	26
173	Evidence of CNS Î²-amyloid deposition in Nasu-Hakola disease due to the TREM2 Q33X mutation. Neurology, 2017, 89, 2503-2505.	1.1	26
174	Regulation of gene transcription in bipolar disorders: Role of DNA methylation in the relationship between prodynorphin and brain derived neurotrophic factor. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 82, 314-321.	4.8	26
175	Disruption of brainstem monoaminergic fibre tracts in multiple sclerosis as a putative mechanism for cognitive fatigue: a fixel-based analysis. NeuroImage: Clinical, 2021, 30, 102587.	2.7	26
176	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. Cortex, 2020, 133, 384-398.	2.4	26
177	Induction of adhesion molecules on human Schwann cells by proinflammatory cytokines, an immunofluorescence study. Journal of the Neurological Sciences, 1999, 170, 124-130.	0.6	25
178	CSF pro-orexin and amyloid-Î²38 expression in Alzheimer's disease and frontotemporal dementia. Neurobiology of Aging, 2018, 72, 171-176.	3.1	25
179	Myosin heavy chain composition of muscle fibers in spinal muscular atrophy. Muscle and Nerve, 1989, 12, 43-51.	2.2	24
180	Synergistic effect of Â-amyloid protein and interferon gamma on nitric oxide production by C2C12 muscle cells. Brain, 2000, 123, 374-379.	7.6	24

#	Article	IF	Citations
181	A novel polymorphism in SEL1L confers susceptibility to Alzheimer's disease. Neuroscience Letters, 2006, 398, 53-58.	2.1	24
182	ICOS gene haplotypes correlate with IL10 secretion and multiple sclerosis evolution. Journal of Neuroimmunology, 2007, 186, 193-198.	2.3	24
183	Cerebrospinal fluid progranulin levels in patients with different multiple sclerosis subtypes. Neuroscience Letters, 2010, 469, 234-236.	2.1	24
184	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 1408-1423.	0.8	24
185	p75 Neurotrophin Receptor Induction and Macrophage Infiltration in Peripheral Nerve during Experimental Diabetic Neuropathy: Possible Relevance on Regeneration. Experimental Neurology, 1997, 146, 206-211.	4.1	23
186	Pharmacological Management of Psychiatric Symptoms in Frontotemporal Dementia: A Systematic Review. Journal of Geriatric Psychiatry and Neurology, 2017, 30, 162-169.	2.3	23
187	The Role of the Innate Immune System in Alzheimerâ€™s Disease and Frontotemporal Lobar Degeneration: An Eye on Microglia. Clinical and Developmental Immunology, 2013, 2013, 1-11.	3.3	22
188	Gene promoter methylation and expression of Pin1 differ between patients with frontotemporal dementia and Alzheimer's disease. Journal of the Neurological Sciences, 2016, 362, 283-286.	0.6	22
189	The distinct roles of monoamines in multiple sclerosis: A bridge between the immune and nervous systems?. Brain, Behavior, and Immunity, 2021, 94, 381-391.	4.1	22
190	Cultures of human Schwann cells isolated from fetal nerves. Brain Research, 1988, 440, 261-266.	2.2	21
191	Induction of p75NGFR in human diabetic neuropathy. Journal of the Neurological Sciences, 1996, 135, 55-62.	0.6	21
192	Presenilin-1 mutation E318G and familial Alzheimer's disease in the Italian population. Neurobiology of Aging, 2007, 28, 1682-1688.	3.1	21
193	Inverse agonism of cannabinoid CB1 receptor blocks the adhesion of encephalitogenic T cells in inflamed brain venules by a protein kinase A-dependent mechanism. Journal of Neuroimmunology, 2011, 233, 97-105.	2.3	21
194	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <scp>NfL</scp> and <scp>pNfH</scp>: A Longitudinal Multicentre Study. Annals of Neurology, 2022, 91, 33-47.	5.3	21
195	The H1 Haplotype of the Tau Gene (MAPT) is Associated with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2010, 19, 909-914.	2.6	20
196	GSK3Î² genetic variability in patients with Multiple Sclerosis. Neuroscience Letters, 2011, 497, 46-48.	2.1	20
197	Possible Influence of a Non-Synonymous Polymorphism Located in the NGF Precursor on Susceptibility to Late-Onset Alzheimer's Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2012, 29, 699-705.	2.6	20
198	Identification of a new susceptibility variant for multiple sclerosis in OAS1 by population genetics analysis. Human Genetics, 2012, 131, 87-97.	3.8	20

#	Article	IF	Citations
199	Comparison of Î²2-microglobulin serum level between Alzheimerâ€™s patients, cognitive healthy and mild cognitive impaired individuals. Biomarkers, 2018, 23, 603-608.	1.9	20
200	Low-affinity nerve growth factor receptor expression in sciatic nerve during P2-peptide induced experimental allergic neuritis. Neuroscience Letters, 1995, 199, 135-138.	2.1	19
201	Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Research, 2010, 1333, 64-71.	2.2	19
202	Evidence of Pre-Synaptic Dopaminergic Deficit in a Patient with a Novel Progranulin Mutation Presenting with Atypical Parkinsonismâ€. Journal of Alzheimer's Disease, 2013, 38, 747-752.	2.6	19
203	Progranulin gene variability influences the risk for bipolar I disorder, but not bipolar II disorder. Bipolar Disorders, 2014, 16, 769-772.	1.9	19
204	Iron in Frontotemporal Lobar Degeneration: A New Subcortical Pathological Pathway?. Neurodegenerative Diseases, 2016, 16, 172-178.	1.4	19
205	Behavioral and Neurophysiological Effects of Transcranial Direct Current Stimulation (tDCS) in Fronto-Temporal Dementia. Frontiers in Behavioral Neuroscience, 2018, 12, 235.	2.0	19
206	CSF Î²-amyloid predicts prognosis in patients with multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1223-1231.	3.0	19
207	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 997-1004.	1.9	19
208	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic C9orf72 Repeat Expansion Adult Carriers. Annals of Neurology, 2020, 88, 113-122.	5.3	19
209	Chemokine network in multiple sclerosis: role in pathogenesis and targeting for future treatments. Expert Review of Neurotherapeutics, 2004, 4, 439-453.	2.8	18
210	Heparan sulfate proteoglycan induces the production of NO and TNF-alpha by murine microglia. Immunity and Ageing, 2005, 2, 11.	4.2	18
211	Absence of TREM2 polymorphisms in patients with Alzheimer's disease and Frontotemporal Lobar Degeneration. Neuroscience Letters, 2007, 411, 133-137.	2.1	18
212	No major progranulin genetic variability contribution to disease etiopathogenesis in an ALS Italian cohort. Neurobiology of Aging, 2011, 32, 1157-1158.	3.1	18
213	Is HCRTR2 a Genetic Risk Factor for Alzheimer's Disease?. Dementia and Geriatric Cognitive Disorders, 2014, 38, 245-253.	1.5	18
214	CHRNA7 Gene and Response to Cholinesterase Inhibitors in an Italian Cohort of Alzheimerâ€™s Disease Patients. Journal of Alzheimer's Disease, 2016, 52, 1203-1208.	2.6	18
215	Genetic Counseling and Testing for Alzheimerâ€™s Disease and Frontotemporal Lobar Degeneration: An Italian Consensus Protocol. Journal of Alzheimer's Disease, 2016, 51, 277-291.	2.6	18
216	PICALM Gene Methylation in Blood of Alzheimerâ€™s Disease Patients Is Associated with Cognitive Decline. Journal of Alzheimer's Disease, 2018, 65, 283-292.	2.6	18

#	Article	IF	Citations
217	Structural and metabolic cerebral alterations between elderly bipolar disorder and behavioural variant frontotemporal dementia: A combined MRI-PET study. Australian and New Zealand Journal of Psychiatry, 2019, 53, 413-423.	2.3	18
218	Extracellular Vesicles in Multiple Sclerosis: Role in the Pathogenesis and Potential Usefulness as Biomarkers and Therapeutic Tools. Cells, 2021, 10, 1733.	4.1	18
219	The expression of CD59 in experimental allergic neuritis. Journal of the Neurological Sciences, 1999, 165, 154-159.	0.6	17
220	E-selectin A561C and G98T polymorphisms influence susceptibility and course of multiple sclerosis. Journal of Neuroimmunology, 2005, 165, 201-205.	2.3	17
221	Association of neuronal nitric oxide synthase C276T polymorphism with Alzheimerâ€™s disease. Journal of Neurology, 2005, 252, 985-986.	3.6	17
222	Candidate gene analysis of IP-10 gene in patients with Alzheimer's disease. Neuroscience Letters, 2006, 404, 217-221.	2.1	17
223	MCP-1 A-2518G Polymorphism: Effect on Susceptibility for Frontotemporal Lobar Degeneration and on Cerebrospinal Fluid MCP-1 Levels. Journal of Alzheimer's Disease, 2009, 17, 125-133.	2.6	17
224	GRN Thr272fs Clinical Heterogeneity: A Case with Atypical Late Onset Presenting with a Dementia with Lewy Bodies Phenotype. Journal of Alzheimer's Disease, 2013, 35, 669-674.	2.6	17
225	Gender Effects on Plasma PGRN Levels in Patients with Alzheimer's Disease: A Preliminary Study. Journal of Alzheimer's Disease, 2013, 35, 313-318.	2.6	17
226	Novel Missense Progranulin Gene Mutation Associated with the Semantic Variant of Primary Progressive Aphasia. Journal of Alzheimer's Disease, 2013, 36, 415-420.	2.6	17
227	Novel Evidence of Phenotypical Variability in the Hexanucleotide Repeat Expansion in Chromosome 9. Journal of Alzheimer's Disease, 2013, 35, 455-462.	2.6	17
228	Progranulin as a therapeutic target for dementia. Expert Opinion on Therapeutic Targets, 2018, 22, 579-585.	3.4	17
229	Role of Chitinase 3â€“like 1 as a Biomarker in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	17
230	Manifesting carrier of X-linked Duchenne muscular dystrophy. Journal of the Neurological Sciences, 1981, 49, 455-463.	0.6	16
231	Analysis of the genes coding for subunit 10 and 15 of cytochrome c oxidase in Alzheimerâ€™s disease. Journal of Neural Transmission, 2009, 116, 1635-1641.	2.8	16
232	Study of thyroid hormone receptor alpha gene polymorphisms on Alzheimer's disease. Neurobiology of Aging, 2011, 32, 624-630.	3.1	16
233	A 66-year-old patient with vanishing white matter disease due to the p.Ala87Val EIF2B3 mutation. Neurology, 2012, 79, 2077-2078.	1.1	16
234	Idalopirdine as a treatment for Alzheimerâ€™s disease. Expert Opinion on Investigational Drugs, 2015, 24, 981-987.	4.1	16

#	Article	IF	Citations
235	Spatiotemporal analysis for detection of pre-symptomatic shape changes in neurodegenerative diseases: Initial application to the GENFI cohort. NeuroImage, 2019, 188, 282-290.	4.2	16
236	Evidence of retinal anterograde neurodegeneration in the very early stages of multiple sclerosis: a longitudinal OCT study. Neurological Sciences, 2020, 41, 3175-3183.	1.9	16
237	Genetics and biology of Alzheimer's disease and frontotemporal lobar degeneration. International Journal of Clinical and Experimental Medicine, 2010, 3, 129-43.	1.3	16
238	Serotonin Transporter Gene Polymorphic Element <i>5-HTTLPR</i> Increases the Risk of Sporadic Parkinsonâ€™s Disease in Italy. European Neurology, 2009, 62, 120-123.	1.4	15
239	Candidate gene analysis of semaphorins in patients with Alzheimerâ€™s disease. Neurological Sciences, 2010, 31, 169-173.	1.9	15
240	A study of the association between the ADAM12 and SH3PXD2A (SH3MD1) genes and Alzheimer's disease. Neuroscience Letters, 2010, 468, 1-2.	2.1	15
241	Genetic variation in the choline O-acetyltransferase gene in depression and Alzheimerâ€™s disease: The VITA and Milano studies. Journal of Psychiatric Research, 2011, 45, 1250-1256.	3.1	15
242	PRNP P39L Variant is a Rare Cause ofÂFrontotemporal Dementia in Italian Population. Journal of Alzheimer's Disease, 2016, 50, 353-357.	2.6	15
243	The Role of Amyloid-Î² in White Matter Damage: Possible Common Pathogenetic Mechanisms in Neurodegenerative and Demyelinating Diseases. Journal of Alzheimer's Disease, 2020, 78, 13-22.	2.6	15
244	Acute ataxia coincident with seroconversion for anti-HIV. Journal of Neurology, 1991, 238, 356-357.	3.6	14
245	Progressive, isolated language disturbance: Its significance in a 65-year-old-man. A case report with implications for treatment and review of literature. Journal of the Neurological Sciences, 2006, 240, 45-51.	0.6	14
246	Polymorphisms in the LOC387715/ARMS2 Putative Gene and the Risk for Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2008, 26, 169-174.	1.5	14
247	SORL1 Gene is Associated with the Conversion from Mild Cognitive Impairment to Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 46, 771-776.	2.6	14
248	Profiling of Ubiquitination Pathway Genes in Peripheral Cells from Patients with Frontotemporal Dementia due to C9ORF72 and GRN Mutations. International Journal of Molecular Sciences, 2015, 16, 1385-1394.	4.1	14
249	P-selectin glycoprotein ligand-1 variable number of tandem repeats (VNTR) polymorphism in patients with multiple sclerosis. Neuroscience Letters, 2005, 388, 149-152.	2.1	13
250	SELPLG and SELP single-nucleotide polymorphisms in multiple sclerosis. Neuroscience Letters, 2006, 394, 92-96.	2.1	13
251	The Serotonin Transporter Promoter Polymorphic Region is not a Risk Factor for Alzheimer's Disease Related Behavioral Disturbances. Journal of Alzheimer's Disease, 2009, 18, 125-130.	2.6	13
252	Appearance of PLP mRNA in Specific Regions of the Developing Rat Lumbosacral Spinal Cord as Revealed by in Situ Hybridization. Experimental Neurology, 1993, 121, 139-147.	4.1	12

#	Article	IF	Citations
253	Role of VEGF gene variability in longevity: A lesson from the Italian population. Neurobiology of Aging, 2008, 29, 1917-1922.	3.1	12
254	NOTCH3 gene mutations in subjects clinically suspected of CADASIL. Journal of the Neurological Sciences, 2011, 307, 144-148.	0.6	12
255	BAG1 is a Protective Factor for Sporadic Frontotemporal Lobar Degeneration but not for Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 23, 701-707.	2.6	12
256	Sciatic endometriosis presenting as periodic (catamenial) sciatic radiculopathy. Journal of Neurology, 2012, 259, 1470-1471.	3.6	12
257	Progranulin genetic polymorphisms influence progression of disability and relapse recovery in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1007-1012.	3.0	12
258	The Neuroanatomy of Somatoform Disorders: A Magnetic Resonance Imaging Study. Psychosomatics, 2019, 60, 278-288.	2.5	12
259	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. Alzheimer's Research and Therapy, 2021, 13, 127.	6.2	12
260	APOE Îµ2 and Îµ4 influence the susceptibility for Alzheimer's disease but not other dementias. International Journal of Molecular Epidemiology and Genetics, 2010, 1, 193-200.	0.4	12
261	Alzheimerâ€™s disease: from molecular pathogenesis to innovative therapies. Expert Review of Neurotherapeutics, 2003, 3, 619-630.	2.8	11
262	Serum folate concentrations in patients with cortical and subcortical dementias. Neuroscience Letters, 2007, 420, 213-216.	2.1	11
263	Failure to Replicate an Association of rs5984894 SNP in the PCDH11X Gene in a Collection of 1,222 Alzheimer's Disease Affected Patients. Journal of Alzheimer's Disease, 2010, 21, 385-388.	2.6	11
264	The Progranulin (GRN) Cys157LysfsX97 Mutation is Associated with Nonfluent Variant of Primary Progressive Aphasia Clinical Phenotype. Journal of Alzheimer's Disease, 2012, 28, 759-763.	2.6	11
265	Progress in Alzheimerâ€™s disease research in the last year. Journal of Neurology, 2013, 260, 1936-1941.	3.6	11
266	Timely Detection of Mild Cognitive Impairment in Italy: An Expert Opinion. Journal of Alzheimer's Disease, 2019, 68, 1401-1414.	2.6	11
267	Parieto-occipital sulcus widening differentiates posterior cortical atrophy from typical Alzheimer disease. NeuroImage: Clinical, 2020, 28, 102453.	2.7	11
268	Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12185.	2.4	11
269	Alpha1-antichymotrypsin induces TNF-Î± production and NF-Î²B activation in the murine N9 microglial cell line. Neuroscience Letters, 2009, 467, 40-42.	2.1	10
270	Emerging amyloid disease-modifying drugs for Alzheimerâ€™s disease. Expert Opinion on Emerging Drugs, 2016, 21, 5-7.	2.4	10

#	Article	IF	Citations
271	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimerâ€™s Disease Patients and Controls after Correction for Ventricular Volumes. Journal of Alzheimer's Disease, 2017, 56, 543-555.	2.6	10
272	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. Biological Psychiatry, 2021, 89, 825-835.	1.3	10
273	Cytochrome c oxidase during human fetal development. International Journal of Developmental Neuroscience, 1989, 7, 5-14.	1.6	9
274	In situ hybridization study of myelin protein mRNA in rats with an experimental diabetic neuropathy. Neuroscience Letters, 1996, 207, 65-69.	2.1	9
275	The urokinase-type plasminogen activator polymorphism PLAU_1 is a risk factor for APOE-Îµ4 non-carriers in the Italian Alzheimerâ€™s disease population and does not affect the plasma AÎ²(1â€“42) level. Neurobiology of Disease, 2007, 25, 609-613.	4.4	9
276	Absence of <i>TARDBP</i> Gene Mutations in an Italian Series of Patients with Frontotemporal Lobar Degeneration. Dementia and Geriatric Cognitive Disorders, 2009, 28, 239-243.	1.5	9
277	Is the ornithine transcarbamylase gene a genetic determinant of Alzheimerâ€™s disease?. Neuroscience Letters, 2009, 449, 76-80.	2.1	9
278	Is KIF24 a genetic risk factor for Frontotemporal Lobar Degeneration?. Neuroscience Letters, 2010, 482, 240-244.	2.1	9
279	Association of HLA class I markers with multiple sclerosis in the Italian and UK population: evidence of two independent protective effects. Journal of Medical Genetics, 2011, 48, 485-492.	3.2	9
280	Genetics and Expression Analysis of the Specificity Protein 4 Gene (SP4) in Patients with Alzheimer's Disease and Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2012, 31, 537-542.	2.6	9
281	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. Molecular Neurodegeneration, 2021, 16, 79.	10.8	9
282	Association study to evaluate the serotonin transporter and apolipoprotein E genes in frontotemporal lobar degeneration in Italy. Journal of Human Genetics, 2008, 53, 1029-1033.	2.3	8
283	Word and Picture Version of the Free and Cued Selective Reminding Test (FCSRT): Is There Any Difference?. Journal of Alzheimer's Disease, 2017, 61, 47-52.	2.6	8
284	Alzheimerâ€™s Disease Diagnosis: Discrepancy between Clinical, Neuroimaging, and Cerebrospinal Fluid Biomarkers Criteria in an Italian Cohort of Geriatric Outpatients: A Retrospective Cross-sectional Study. Frontiers in Medicine, 2017, 4, 203.	2.6	8
285	Disease-related cortical thinning in presymptomatic granulin mutation carriers. NeuroImage: Clinical, 2021, 29, 102540.	2.7	8
286	miR-150-5p and let-7b-5p in Blood Myeloid Extracellular Vesicles Track Cognitive Symptoms in Patients with Multiple Sclerosis. Cells, 2022, 11, 1551.	4.1	8
287	Myelin protein transcripts increase in experimental diabetic neuropathy. Neuroscience Letters, 1993, 161, 203-206.	2.1	7
288	Interaction between the APOE É›4 allele and the APH-1b c+651T>G SNP in Alzheimer's disease. Neurobiology of Aging, 2008, 29, 1494-1501.	3.1	7

#	Article	IF	Citations
289	Candidate gene analysis of selectin cluster in patients with multiple sclerosis. Journal of Neurology, 2009, 256, 832-833.	3.6	7
290	CCL8/MCP-2 association analysis in patients with Alzheimerâ€™s disease and frontotemporal lobar degeneration. Journal of Neurology, 2009, 256, 1379-1381.	3.6	7
291	BalÃ²â€™s concentric sclerosis: still to be considered as a variant of multiple sclerosis?. Neurological Sciences, 2015, 36, 2277-2280.	1.9	7
292	The Novel GRN g.1159_1160delTG Mutation is Associated with Behavioral Variant Frontotemporal Dementia. Journal of Alzheimer's Disease, 2015, 44, 277-282.	2.6	7
293	Non Fluent Variant of Primary Progressive Aphasia Due to the Novel GRN g.9543delA(IVS3-2delA) Mutation. Journal of Alzheimer's Disease, 2016, 54, 717-721.	2.6	7
294	C9orf72, age at onset, and ancestry help discriminate behavioral from language variants in FTLD cohorts. Neurology, 2020, 95, e3288-e3302.	1.1	7
295	Letters to the editor. Muscle and Nerve, 1984, 7, 493-499.	2.2	6
296	Cultured human monocytes release proinflammatory cytokines in response to myelin basic protein. Neuroscience Letters, 1998, 252, 151-154.	2.1	6
297	Candidate gene analysis of SPARCL1 gene in patients with multiple sclerosis. Neuroscience Letters, 2007, 425, 173-176.	2.1	6
298	FUS/TLS Genetic Variability in Sporadic Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2010, 19, 1317-1322.	2.6	6
299	Position paper of the Italian Society for the study of Dementias (Sindem) on the proposal of a new Lexicon on Alzheimer disease. Neurological Sciences, 2012, 33, 201-208.	1.9	6
300	C9ORF72 repeat expansion not detected in patients with multiple sclerosis. Neurobiology of Aging, 2014, 35, 1213.e1-1213.e2.	3.1	6
301	Rapidly progressive primary progressive aphasia and parkinsonism with novel GRN mutation. Movement Disorders, 2017, 32, 476-478.	3.9	6
302	Epigenetic regulatory modifications in genetic and sporadic frontotemporal dementia. Expert Review of Neurotherapeutics, 2018, 18, 469-475.	2.8	6
303	Analysis of C9orf72 Intermediate Alleles in a Retrospective Cohort of Neurological Patients: Risk Factors for Alzheimerâ€™s Disease?. Journal of Alzheimer's Disease, 2021, 81, 1445-1451.	2.6	6
304	Association of rs3027178 polymorphism in the circadian clock gene PER1 with susceptibility to Alzheimerâ€™s disease and longevity in an Italian population. GeroScience, 2022, 44, 881-896.	4.6	6
305	A Novel Study and Meta-Analysis of the Genetic Variation of the Serotonin Transporter Promoter in the Italian Population Do Not Support a Large Effect on Alzheimer's Disease Risk. International Journal of Alzheimer's Disease, 2011, 2011, 1-7.	2.0	5
306	Phenotypic Variability associated with the C9ORF72 Hexanucleotide Repeat Expansion: A Sporadic Case of Frontotemporal Lobar Degeneration with Prodromal Hyposmia and Predominant Semantic Deficits. Journal of Alzheimer's Disease, 2014, 40, 849-855.	2.6	5

#	Article	IF	Citations
307	Low CSF Î²-amyloid levels predict early regional grey matter atrophy in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 39, 101899.	2.0	5
308	CSF Î²-amyloid predicts early cerebellar atrophy and is associated with a poor prognosis in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 37, 101462.	2.0	5
309	White Matter Hyperintensities Are No Major Confounder for Alzheimerâ€™s Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2021, 79, 163-175.	2.6	5
310	Niemann-Pick Type C 1 (NPC1) and NPC2 Gene Variability in Demented Patients with Evidence of Brain Amyloid Deposition. Journal of Alzheimer's Disease, 2021, 83, 1313-1323.	2.6	5
311	Behavioral Genetics of Neurodegenerative Disorders. Current Topics in Behavioral Neurosciences, 2011, 12, 615-631.	1.7	4
312	Effects of Multiple Genetic Loci on Age atÂOnset in Frontotemporal Dementia. Journal of Alzheimer's Disease, 2017, 56, 1271-1278.	2.6	4
313	Self-Awareness for Memory Impairment in Amnestic Mild Cognitive Impairment: A Longitudinal Study. American Journal of Alzheimer's Disease and Other Dementias, 2017, 32, 401-407.	1.9	4
314	Intensive versus standard lowering of blood pressure in the acute phase of intracranial haemorrhage: a systematic review and meta-analysis. Internal and Emergency Medicine, 2018, 13, 95-105.	2.0	4
315	Monozygotic Twins with Frontotemporal Dementia Due To Thr272fs GRN Mutation Discordant for Age At Onset. Journal of Alzheimer's Disease, 2019, 67, 1173-1179.	2.6	4
316	C9ORF72 hexanucleotide repeat expansion frequency in patients with Paget's disease of bone. Neurobiology of Aging, 2020, 85, 154.e1-154.e3.	3.1	4
317	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. Scientific Reports, 2020, 10, 12184.	3.3	4
318	Case Report: Efficacy of Rituximab in a Patient With Familial Mediterranean Fever and Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 591395.	2.4	4
319	In vivo evidence of functional disconnection between brainstem monoaminergic nuclei and brain networks in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 56, 103224.	2.0	4
320	Usefulness of Multi-Parametric MRI for the Investigation of Posterior Cortical Atrophy. PLoS ONE, 2015, 10, e0140639.	2.5	4
321	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. Alzheimer's Research and Therapy, 2022, 14, 10.	6.2	4
322	Alterations of the miR-126-3p/POU2AF1/Spi-B Axis and JCPyV Reactivation in Multiple Sclerosis Patients Receiving Natalizumab. Frontiers in Neurology, 2022, 13, 819911.	2.4	4
323	Immunocytochemical expression of human muscle cell p75 neurotrophin receptor is down-regulated by cyclic adenosine 3â€²,5â€²-monophosphate. Neuroscience Letters, 1997, 234, 79-82.	2.1	3
324	Severe polyneuropathy in a patient with Churg-Strauss syndrome. Journal of the Peripheral Nervous System, 2000, 5, 106-110.	3.1	3

#	Article	IF	Citations
325	Partial recovery after severe immune reconstitution inflammatory syndrome in a multiple sclerosis patient with progressive multifocal leukoencephalopathy. Immunotherapy, 2014, 6, 23-28.	2.0	3
326	Brain temperature in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 894-896.	3.0	3
327	Plasma Screening for Progranulin Mutations in Patients with Progressive Supranuclear Palsy and Corticobasal Syndromes. Journal of Alzheimer's Disease, 2016, 53, 445-449.	2.6	3
328	A Critical Review on Structural Neuroimaging Studies in BD: a Transdiagnostic Perspective from Psychosis to Fronto-Temporal Dementia. Current Behavioral Neuroscience Reports, 2020, 7, 86-95.	1.3	3
329	No association of IFI16 (interferon-inducible protein 16) variants with susceptibility to multiple sclerosis. Journal of Neuroimmunology, 2014, 271, 49-52.	2.3	2
330	Transmembrane Protein 106B Gene (TMEM106B) Variability and Influence on Progranulin Plasma Levels in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 43, 757-761.	2.6	2
331	Frontotemporal Lobar Degeneration. , 2015, , 57-66.		2
332	Profiling of Specific Gene Expression Pathways in Peripheral Cells from Prodromal Alzheimerâ€™s Disease Patients. Journal of Alzheimer's Disease, 2018, 61, 1289-1294.	2.6	2
333	Detection of the SQSTM1 Mutation in a Patient with Early-Onset Hippocampal Amnestic Syndrome. Journal of Alzheimer's Disease, 2021, 79, 477-481.	2.6	2
334	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. Cortex, 2022, 150, 12-28.	2.4	2
335	Alzheimerâ€™s disease: from pathogenesis to novel therapeutic approaches. Therapy: Open Access in Clinical Medicine, 2009, 6, 259-277.	0.2	1
336	Cell-dependent kinase inhibitor 2A and 2B genetic variability in patients with Alzheimerâ€™s disease. Journal of Neurology, 2011, 258, 704-705.	3.6	1
337	Progress in multiple sclerosis research in the last year. Journal of Neurology, 2012, 259, 1497-1501.	3.6	1
338	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. Neurobiology of Aging, 2022, , .	3.1	1
339	The <scp>CBIâ€R</scp> detects early behavioural impairment in genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2022, 9, 644-658.	3.7	1
340	Lack of Association between the GPR3 Gene and the Risk for Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-3.	2.0	0
341	Interview: Alzheimerâ€™s disease: new paradigms for neurologists. Therapy: Open Access in Clinical Medicine, 2011, 8, 473-474.	0.2	0
342	Disease-modifying drugs in multiple sclerosis: new oral options. Clinical Practice (London, England), 2012, 9, 315-327.	0.1	0

#	Article	IF	Citations
343	Ask the Experts: Progress in diagnosing frontotemporal lobar dementia. Neurodegenerative Disease Management, 2012, 2, 251-254.	2.2	0
344	Diogenes syndrome in dementia: a case report. BJPsych Open, 2021, 7, e43.	0.7	0
345	Teaching Neuroimage: Crowned Dens Syndrome, an Acute Attack of Calcium Pyrophosphate Deposition Disease Mimicking Acute Meningitis. Neurology, 0, , 10.1212/WNL.0000000000200949.	1.1	0